Glucotrack (GCTK) Equity Average (2011 - 2025)

Glucotrack has disclosed Equity Average across 15 years of filings, most recently posting $2.8 million for Q4 2025.

• Quarterly Equity Average rose 132.78% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 132.78% YoY) and the FY2025 annual result came in at -$5.1 million, down 3.76% from the prior year.
• Equity Average retreated to $2.8 million in Q4 2025, from $4.8 million in the prior quarter.
• Over five years, Equity Average peaked at $8.6 million in Q1 2021 and troughed at -$8.5 million in Q4 2024.
• A 5-year average of $2.9 million and a median of $3.8 million in 2022 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2024 — Equity Average sank 294.45% — and 2025, when it jumped 585.35%.
• Tracing GCTK's Equity Average over 5 years: stood at $5.8 million in 2021, then sank by 69.24% to $1.8 million in 2022, then surged by 144.18% to $4.4 million in 2023, then plunged by 294.45% to -$8.5 million in 2024, then jumped by 132.78% to $2.8 million in 2025.
• Business Quant data shows GCTK's Equity Average at $2.8 million in Q4 2025, $4.8 million in Q3 2025, and $7.1 million in Q2 2025.